STAT Plus: Johnson & Johnson invests in Thirty Madison, signaling the resilience of pharma’s interest in health tech
Late last year, several high-profile partnerships between big pharma companies and health tech startups fell…
Category: finance
STAT Plus: Teladoc rival MDLive is preparing to go public next year
On the heels of Teladoc’s landscape-shifting deal to buy Livongo, telemedicine rival MDLive is setting…
STAT Plus: 4 questions for neurology startups as venture investors pour millions into the field
As pharmaceutical companies stepped back from developing new drugs for neurological conditions, venture capitalists took…
Listen: A health tech mega-deal, a Twitter vaccine debate, and media criticism from Operation Warp Speed
Does the future of health tech look like Facebook? Can we cut corners with Covid-19…
STAT Plus: 10 burning questions about Teladoc’s $18.5 billion deal to buy Livongo
It’s hard to recall a deal that scrambled the dynamics of the health tech industry…
Blackstone agrees to buy Ancestry in $4.7 billion deal
Investment firm Blackstone announced on Wednesday that it was scooping up direct-to-consumer genetics company Ancestry…
Teladoc Health and Livongo merge in an $18.5 billion deal
Telemedicine provider Teladoc Health and diabetes coaching company Livongo have agreed to merge in an…
STAT Plus: Earnings season highlights how health tech companies fared in the first full quarter of the pandemic
It’s earnings season for health tech companies — and that’s opening a window into how…
Medical nonprofits forced to scale back as the pandemic upends their fundraising
Medical charities have long relied on black-tie galas, golf tournaments, and bike-a-thons to fund their…
Listen: Inside the NBA bubble, a DIY coronavirus vaccine, and the real VC numbers
How much should a Covid-19 vaccine cost? What can basketball teach us about pandemic safety?…
STAT Plus: Venture capitalists are still showering biotechs with cash, even as the coronavirus upends markets
Venture capitalists are still spending big on biotech companies, even four months after the coronavirus…
STAT Plus: MacKenzie Scott, with a massive Amazon fortune, emerges as a public health philanthropist
You may not know the name MacKenzie Scott – the author just started going by…
STAT Plus: Among biotech venture capital firms, Flagship Pioneering got the best single-fund returns
A fund launched in 2012 by the biotech venture capital firm Flagship Pioneering is on…
Opinion: Invest in community-based organizations to put health dollars where they are really needed
If it wasn’t already clear that the U.S. does a poor job of investing in…
STAT Plus: Seeking EU approval on acquisition, Google pledges not to use Fitbit health data to target ads
With the clock ticking on a European Commission probe into Google’s $2.1 billion bid for…
STAT Plus: As European Commission decision looms, Google faces continued scrutiny over Fitbit deal
Google is again facing questions from regulators about its $2.1 billion bid for Fitbit. The…
STAT Plus: Proving predictions wrong, health tech funding keeps climbing
Despite forecasts that investments in health tech would dry up by mid-year, venture funding for…
STAT Plus: Smart pill maker Proteus files for bankruptcy, reveals it has held acquisition talks with Otsuka
Smart pill maker Proteus Digital Health on Monday filed for Chapter 11 bankruptcy, the latest…
Opinion: Fee for service is a terrible way to pay for health care. Try a subscription model instead
Amid the nightly roar of applause for health care workers courageously caring for Covid-19 patients,…
STAT Plus: ‘An extremely volatile time’: New report underscores the recent rollercoaster of the biotech market
A new report from BIO shows just how chaotic the last few years have been…
STAT Plus: Medical device startup raises almost $44M to advance a less-invasive treatment for fluid in the brain
A Massachusetts medical device startup said Tuesday it has raised $43.9 million in venture capital…
STAT Plus: Why would AstraZeneca want to buy Gilead? Some analysts say it’s not entirely clear
Amid intense interest in Gilead Sciences (GILD) thanks to its experimental Covid-19 drug, an out-of-left-field…
Opinion: Covid-19 is changing the game for health care companies and investors
Even as the health care industry has stepped up with an unprecedented response to the…
STAT Plus: In a first for RNA-modifying drugs, AstraZeneca partners with startup Accent Therapeutics
Drug giant AstraZeneca is moving deeper into RNA-based therapies with a new partnership with the…
STAT Plus: Despite economic downturn, big names in health tech are drawing in significant funding
It was expected to be a last-minute salvo: As much of the world braced for…
STAT Plus: After years of manufacturing problems, Akorn files for bankruptcy protection
After mounting financial and manufacturing woes, Akorn (AKRX) has filed for bankruptcy protection, a humbling…
Opinion: Three traps for the unwary in HHS’ provider relief fund
In its rush to offer a lifeline to U.S. health care providers struggling under the…
STAT Plus: Dyne Therapeutics and three other startups got venture funding a year ago. Will it be enough to get them through Covid-19?
How a venture-backed startup gets its money is suddenly more fraught than it used to…
STAT Plus: FTC approves AbbVie’s $63 million deal for Allergan amid scornful dissent
After months of deliberation, the Federal Trade Commission approved AbbVie’s (ABBV) $63 billion acquisition of…
Opinion: How biopharma companies can keep ‘feeding the beast’ in the time of coronavirus
My colleagues and I lead and support the finance function of more than 160 biopharma…
STAT Plus: Covid-19 is forcing smaller biotechs to cut spending and change financing plans
The Covid-19 pandemic is taking a harsh toll on small biotech companies, many of which…
STAT Plus: A gulf emerges in health tech: While some companies surge, others lay off their workers
You might expect them to be pandemic-proof: They’re the companies offering glimpses of the future…
STAT Plus: The coronavirus pandemic could shrink some biotech startup valuations
Determining a private company’s value means estimating how and when it might be able to…
STAT Plus: On a 180-person video chat, biotech executives share the best ways do business amid the coronavirus
Given the hour — 4:30 a.m. in California, 7:30 a.m. in Boston — no one…
STAT Plus: Dozens of financial firms want pharma to place Covid-19 patients over profits
More than three dozen asset managers, pension funds, and insurers are urging the pharmaceutical industry…
.jpg)
STAT Plus: Biotech venture capital had a record-breaking quarter, but isn’t out of the woods yet
A version of this story also appeared in STAT’s daily biotech newsletter, The Readout. Subscribe…
STAT Plus: A rare investment mechanism is helping to fund some health tech companies’ coronavirus projects
Extraordinary times call for extraordinary financing instruments, according to one California venture capital firm. A…
Coronavirus-related layoffs hit health tech startups
With the economy in freefall amid the coronavirus pandemic, some health tech startups have started…
STAT Plus: Digital health startups scored a critical cash infusion at the start of this year
As much of the world prepares for the possibility of a coronavirus-driven recession, a new…
STAT Plus: Big biotech venture funds raise billions despite coronavirus fears
The economy is grinding to a near-halt because of Covid-19. In the biotechnology sector, which…
Amid coronavirus, private equity-backed company slashes benefits for emergency room doctors
WASHINGTON — A private equity-backed health care company is slashing its doctors’ benefits in response…
STAT Plus: STAT Plus video chat: Biotech in uncharted territory
Every corner of the biotech industry is being impacted by the coronavirus pandemic. There will…
Opinion: The economic rationale for strong action now against Covid-19
As governments and communities struggle to figure out the best way to deal with the…
.jpg)
STAT Plus: As the market craters, Keros Therapeutics files for an IPO
Keros Therapeutics is filing for an IPO, according to plans made public Monday — a…
Opinion: Overreaction may be a bigger threat to public health than the novel coronavirus
In many infectious diseases, the immune system’s reaction to a virus, bacteria, or other pathogen…
STAT Plus: Kymera announces $102 million in new funding to develop treatments for diseases such as blood cancers
Four years after it was founded, Kymera Therapeutics said Thursday that it has now raised…
STAT Plus: Private equity firms are increasingly buying up doctors’ offices. What does that mean for doctors — or for patients?
WASHINGTON — Can private equity firms provide quality health care? It’s the question that patients,…
STAT Plus: This biotech went public during the stock market’s worst week since 2008
Concerns about the coronavirus outbreak made last week one of the markets’ worst since the…
STAT Plus: Something Ventured: Vor Biopharma and 3 other startups got venture funding a year ago. Did it help them do what they said it would?
This story is part of STAT’s quarterly series Something Ventured, which looks at early-stage startups….
Opinion: Physician practice consolidation: It’s only just begun
Disruption has redefined health care in the past decade. For private practice physicians, the biggest…